<p>克利夫兰，2025 年 12 月 31 日（全球新闻稿）——Abeona Therapeutics Inc.（纳斯达克：ABEO）今天宣布已向新加入公司的执行和非执行员工授予股权奖励。这些股权奖励是根据纳斯达克上市规则 5635(c)(4) 批准的。</p>
<p>在 2025 年 12 月 30 日，Abeona 董事会的薪酬委员会向七名新聘员工授予了限制性股票股权奖励，作为就业的重要诱因，这些股权奖励总计涉及最多 79,584 股 Abeona 普通股。受限股票奖励所涉及的三分之一股份将在授予日期的每个周年日逐年归属，因此授予每位员工的受限股票奖励将在授予日期的第三个周年日完全归属，前提是每位员工在适用的归属日期继续在 Abeona 工作。</p>
<p><strong>关于 Abeona Therapeutics</strong></p>
<p>Abeona Therapeutics Inc.是一家商业阶段的生物制药公司，专注于开发针对严重疾病的细胞和基因疗法。Abeona 的 ZEVASKYN®（prademagene zamikeracel）是首个也是唯一一个用于治疗成人和儿童隐性营养不良性表皮松解症（RDEB）伤口的自体细胞基因疗法。该公司的全整合细胞和基因疗法 cGMP 生产设施位于俄亥俄州克利夫兰，作为 ZEVASKYN 商业生产的制造基地。公司的开发组合包括针对眼科疾病的腺病毒相关病毒（AAV）基因疗法，这些疾病具有很高的未满足医疗需求。Abeona 的新一代 AAV 衣壳正在评估用于多种毁灭性疾病。有关更多信息，请访问 www.abeonatherapeutics.com。</p>
<p>ZEVASKYN®、Abeona Assist®、Abeona Therapeutics®及其相关标志是 Abeona Therapeutics Inc.的商标。</p>
<p><strong>前瞻性声明</strong></p>
<p><em>本新闻稿包含某些根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义属于前瞻性声明的内容，并涉及风险和不确定性。我们试图通过 “可能”、“将”、“相信”、“预期”、“打算”、“潜在” 等术语（以及其他引用未来事件、条件或情况的词语或表达）来识别前瞻性声明。这些术语构成并旨在识别前瞻性声明。实际结果可能因各种重要因素、众多风险和不确定性而与这些前瞻性声明所指示的结果有重大差异，包括但不限于我们成功商业化和市场化 ZEVASKYN 的能力，包括制造足够的 ZEVASKYN 批次以满足需求；ZEVASKYN 的治疗潜力；ZEVASKYN 的未满足需求和市场机会是否与公司的预期一致；我们在稀有疾病组合中的持续兴趣；我们在临床试验中招募患者的能力；与 FDA 或其他监管机构的未来会议和检查的结果，包括与临床前项目和 ZEVASKYN 的 cGMP 生产相关的结果；我们获得或实现必要的监管批准的能力；金融市场和全球经济条件的任何变化的影响，包括因美国贸易政策的变化（如当前或未来的关税）而导致的变化；与数据分析和报告相关的风险；以及在公司最近的 10-K 表格年度报告和随后向证券交易委员会提交的定期报告中披露的其他风险。公司没有义务修订这些前瞻性声明或更新它们以反映本新闻稿日期后发生的事件或情况，无论是由于新信息、未来发展还是其他原因，除非联邦证券法要求。</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qSTNNQ00zTXpNek9Ea3lJekl3TVRrM09ERT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qSTNNQ00zTXpNek9Ea3lJekl3TVRrM09ERT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODQwMDQ0NjUtN2ExZS00ODMzLTllODAtYTZiYTA5NTI1ZDBhLTEwMzEzNTMtMjAyNS0xMi0zMS1lbg==/tiny/Abeona-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODQwMDQ0NjUtN2ExZS00ODMzLTllODAtYTZiYTA5NTI1ZDBhLTEwMzEzNTMtMjAyNS0xMi0zMS1lbg==/tiny/Abeona-Therapeutics-Inc-.png"/></p>
<pre><code> 联系人：投资者和媒体 Greg Gin 投资关系与企业传播副总裁 Abeona Therapeuticsir@abeonatherapeutics.com 投资者 Lee M. SternMeru Advisorslstern@meruadvisors.com
</code></pre>

Abeona治疗

<p>Abeona Therapeutics Inc. 宣布根据纳斯达克上市规则 5635(c)(4) 向新员工授予股权奖励。2025 年 12 月 30 日，薪酬委员会批准了对七名新员工的限制性股票奖励，总计高达 79,584 股，这些股票将在三年内逐步归属。Abeona 是一家专注于细胞和基因疗法的生物制药公司，包括其用于治疗隐性营养性大疱性表皮松解症的产品 ZEVASKYN。该公司强调了其前瞻性声明中关于商业化和监管批准的潜在风险和不确定性</p>

<p>CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>克利夫兰，2025 年 12 月 31 日（全球新闻稿）——Abeona Therapeutics Inc.（纳斯达克：ABEO）今天宣布已向新加入公司的执行和非执行员工授予股权奖励。这些股权奖励是根据纳斯达克上市规则 5635(c)(4) 批准的。</p>
</div><p>On December 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 79,584 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.</p>
<div class="lb-trans"><p>在 2025 年 12 月 30 日，Abeona 董事会的薪酬委员会向七名新聘员工授予了限制性股票股权奖励，作为就业的重要诱因，这些股权奖励总计涉及最多 79,584 股 Abeona 普通股。受限股票奖励所涉及的三分之一股份将在授予日期的每个周年日逐年归属，因此授予每位员工的受限股票奖励将在授予日期的第三个周年日完全归属，前提是每位员工在适用的归属日期继续在 Abeona 工作。</p>
</div><p><strong>About Abeona Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Abeona Therapeutics</strong></p>
</div><p>Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.</p>
<div class="lb-trans"><p>Abeona Therapeutics Inc.是一家商业阶段的生物制药公司，专注于开发针对严重疾病的细胞和基因疗法。Abeona 的 ZEVASKYN®（prademagene zamikeracel）是首个也是唯一一个用于治疗成人和儿童隐性营养不良性表皮松解症（RDEB）伤口的自体细胞基因疗法。该公司的全整合细胞和基因疗法 cGMP 生产设施位于俄亥俄州克利夫兰，作为 ZEVASKYN 商业生产的制造基地。公司的开发组合包括针对眼科疾病的腺病毒相关病毒（AAV）基因疗法，这些疾病具有很高的未满足医疗需求。Abeona 的新一代 AAV 衣壳正在评估用于多种毁灭性疾病。有关更多信息，请访问 www.abeonatherapeutics.com。</p>
</div><p>ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.</p>
<div class="lb-trans"><p>ZEVASKYN®、Abeona Assist®、Abeona Therapeutics®及其相关标志是 Abeona Therapeutics Inc.的商标。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p><em>This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.</em></p>
<div class="lb-trans"><p><em>本新闻稿包含某些根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义属于前瞻性声明的内容，并涉及风险和不确定性。我们试图通过 “可能”、“将”、“相信”、“预期”、“打算”、“潜在” 等术语（以及其他引用未来事件、条件或情况的词语或表达）来识别前瞻性声明。这些术语构成并旨在识别前瞻性声明。实际结果可能因各种重要因素、众多风险和不确定性而与这些前瞻性声明所指示的结果有重大差异，包括但不限于我们成功商业化和市场化 ZEVASKYN 的能力，包括制造足够的 ZEVASKYN 批次以满足需求；ZEVASKYN 的治疗潜力；ZEVASKYN 的未满足需求和市场机会是否与公司的预期一致；我们在稀有疾病组合中的持续兴趣；我们在临床试验中招募患者的能力；与 FDA 或其他监管机构的未来会议和检查的结果，包括与临床前项目和 ZEVASKYN 的 cGMP 生产相关的结果；我们获得或实现必要的监管批准的能力；金融市场和全球经济条件的任何变化的影响，包括因美国贸易政策的变化（如当前或未来的关税）而导致的变化；与数据分析和报告相关的风险；以及在公司最近的 10-K 表格年度报告和随后向证券交易委员会提交的定期报告中披露的其他风险。公司没有义务修订这些前瞻性声明或更新它们以反映本新闻稿日期后发生的事件或情况，无论是由于新信息、未来发展还是其他原因，除非联邦证券法要求。</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qSTNNQ00zTXpNek9Ea3lJekl3TVRrM09ERT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjI3MCM3MzMzODkyIzIwMTk3ODE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODQwMDQ0NjUtN2ExZS00ODMzLTllODAtYTZiYTA5NTI1ZDBhLTEwMzEzNTMtMjAyNS0xMi0zMS1lbg==/tiny/Abeona-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ODQwMDQ0NjUtN2ExZS00ODMzLTllODAtYTZiYTA5NTI1ZDBhLTEwMzEzNTMtMjAyNS0xMi0zMS1lbg==/tiny/Abeona-Therapeutics-Inc-.png"/></p>
<pre><code>Contacts:Investor and MediaGreg GinVP, Investor Relations and Corporate CommunicationsAbeona Therapeuticsir@abeonatherapeutics.comInvestorLee M. SternMeru Advisorslstern@meruadvisors.com
</code></pre>
<div class="lb-trans"><pre><code> 联系人：投资者和媒体 Greg Gin 投资关系与企业传播副总裁 Abeona Therapeuticsir@abeonatherapeutics.com 投资者 Lee M. SternMeru Advisorslstern@meruadvisors.com
</code></pre>
</div>

Abeona 治疗®宣布根据纳斯达克上市规则 5635(c)(4) 授予新的员工诱导股权 | ABEO 股票新闻